What is the brand name for raloxifene?
Raloxifene belongs to a class of drugs known as selective estrogen receptor modulators-SERMs. Raloxifene should not be used before menopause. Raloxifene should not be used to prevent heart disease. Raloxifene is available under the following different brand names: Evista.
How long should a woman take Evista?
In the STAR trial, women took Evista for 5 years. Depending on your unique situation, your doctor may recommend that you take Evista for a longer or shorter amount of time.
Who should not take Evista?
Women who have or have had blood clots 99 in the legs, lungs, or eyes should not take EVISTA. 100 • Women who have had a heart attack or are at risk for a heart attack may have an 101 increased risk of dying from stroke when taking EVISTA.
How many years can you take Evista?
While available information is supportive of EVISTA use for more than three years, the optimum duration of EVISTA therapy is not known.
What is the medication classification of raloxifene Evista?
Raloxifene belongs to a class of drugs known as selective estrogen receptor modulators-SERMs. This medication should not be used before menopause.It should not be used to prevent heart disease.
What is the best time of day to take Evista?
You can take raloxifene at whatever time of day you find easiest to remember but try to take your doses at the same time of day, each day. This will help you to remember to take your doses regularly. You can take the tablet either before or after a meal. If you forget to take a dose, take it as soon as you remember.
What happens when you stop taking raloxifene?
discontinuation). Patients, who discontinued alendronate therapy experienced an increase in bone turnover. Bone turnover increases were less pronounced in patients taking raloxifene and were absent in those who continued alendronate.
Does Evista make you gain weight?
Does raloxifene (Evista) cause weight gain? In a study of postmenopausal women taking raloxifene (Evista) for the prevention of osteoporosis, 9% of women experienced weight gain. It’s important to note that hormonal changes in the body during menopause and other factors can also contribute to weight gain.
How long should you stay on raloxifene?
Background: Due to the chronic nature of osteoporosis and the risk of invasive breast cancer, raloxifene 60 mg/day (raloxifene) is intended to be used for long-term treatment (treatment >3 years).
What is a serious adverse effect that may occur with use of raloxifene?
Seek immediate medical attention if any of these unlikely but serious side effects occur: leg swelling/pain, trouble breathing, chest pain, sudden vision changes, severe headache, weakness on one side of the body, confusion. A very serious allergic reaction to this drug is rare.
What is the drug classification for raloxifene?
Raloxifene is in a class of medications called selective estrogen receptor modulators (SERMs). Raloxifene prevents and treats osteoporosis by mimicking the effects of estrogen (a female hormone produced by the body) to increase the density (thickness) of bone.
What are the possible side effects of Evista (raloxifene)?
There are 5 disease interactions with Evista (raloxifene): Major Potential Hazard, High plausibility. Applicable conditions: Thrombotic/Thromboembolic Disorder, History – Thrombotic/Thromboembolic Disorder, Congestive Heart Failure, Pulmonary Embolism
What is Evista used to treat?
Evista (raloxifene hydrochloride) is an estrogen agonist/antagonist used to treat or prevent osteoporosis in postmenopausal women. Evista is also used to reduce the risk of invasive breast cancer in postmenopausal women who have osteoporosis or who are otherwise at risk of invasive breast cancer.
Is evevista an estrogen agonist/antagonist?
EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds.
How does raloxifene work to treat osteoporosis?
Raloxifene is used to help prevent and treat thinning of the bones ( osteoporosis) only in postmenopausal women. It works like an estrogen to stop the bone loss that can develop in women after menopause, but it does not increase the bone density as much as daily 0.625 mg doses of conjugated estrogens.